comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 23:03:42 - browse：52659

President Biden's White House announced the first 10 medicines that will be up first in its new drug price negotiation program. Anna Moneymaker/Getty Images

WASHINGTON — Medicare on Tuesday announced it will negotiate prices for 10 drugs, including major blood thinners and diabetes medications, in the first round of its negotiation program created in Democrats’ drug pricing reform law.

The drugs include Bristol Myers Squibb’s blood thinner Eliquis, Boehringer Ingelheim and Eli Lilly’s diabetes drug Jardiance, Johnson & Johnson’s blood thinner Xarelto, Merck’s diabetes drug Januvia, AstraZeneca’s diabetes drug Farxiga, Novartis’ heart failure treatment Entresto, Amgen’s rheumatoid arthritis drug Enbrel, Johnson & Johnson and AbbVie’s blood cancer treatment Imbruvica, J&J’s anti-inflammatory medicine Stelara, and Novo Nordisk insulins that go by names including Fiasp and NovoLog.

The new prices will be announced on Sept. 1, 2024, and will go into effect on Jan. 1, 2026. The drugs were chosen from a list of 50 treatments that cost Medicare’s pharmacy drug benefit the most money. The selected medicines cost Medicare more than $50 billion and made up 20% of the Medicare program’s pharmacy drug costs over a one-year period, the Department of Health and Human Services said. (Read more here about the winners and losers of the selection.)

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Elevance, SCAN deals highlight health insurer acquisition scrutiny

hotspot

WSS

WATCH: Why do our ears pop?

Hospitals are piloting generative AI tools as regulators play catch

The world needs the new pandemic treaty

New research sheds light on how often breast cancer is overdiagnosed

J&J reports mixed data on next

Congress: Prevent baby formula shortages by passing a new bill

explore

comprehensive

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

Unmasking the 'centricity' illusion in clinical trials

State Dept. review finds Biden bears some blame for Afghanistan failures

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

After affirmative action ruling, medical educators look to 'holistic review'

A new drug could help frostbite victims avoid its ravages

Medical leaders decry Supreme Court decision on affirmative action

In 'major milestone,' FDA approves first cell therapy for solid tumors

Trump demands the U.S. pay no more for drugs than other countries … again

Pharma’s losing bet in New Jersey

leisure time

Clinicians often fail to acknowledge the pain caused by long Covid

Ukraine seeks to reclaim its role as a hub for clinical trials

Weight loss drugs aren’t covered by Obamacare. That may change

Decentralized clinical trials need collaboration to achieve wider use

MD Anderson's Padmanee Sharma responds to research credit suit

New research sheds light on how often breast cancer is overdiagnosed

Wikipedia

knowledge

hotspot

entertainment